Form 4: Scholar Rock COO Granted 47,021 RSUs

Scholar Rock Holding Corp's Chief Operating Officer, Keith Woods, was granted 47,021 restricted stock units, vesting over four years.

Summary

• Keith Woods, Chief Operating Officer of Scholar Rock Holding Corp (SRRK), was granted 47,021 restricted stock units (RSUs) on February 9, 2026.
• Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting.
• These RSUs are subject to time-based vesting conditions, with the shares vesting in four annual installments over four years.
• The first annual installment is scheduled to vest on January 15, 2027, with subsequent installments vesting annually thereafter, contingent on continued service.
• Following this transaction, Keith Woods beneficially owns a total of 630,275 securities, comprising 33,254 shares of common stock, 147,021 time-based RSUs (which include this grant), and 450,000 performanceand time-based RSUs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at retention and alignment, without indicating any significant operational or financial shifts.

Positives

• The grant of 47,021 restricted stock units (RSUs) to the Chief Operating Officer, Keith Woods, aligns his interests with long-term shareholder value.
• The time-based vesting schedule over four years encourages executive retention and sustained performance.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports an executive compensation event.

Risks

• This Form 4 filing does not contain information regarding company-specific risks. It is solely a disclosure of an insider transaction.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction. It details an executive compensation event.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock units (RSUs) with multi-year vesting schedules, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to incentivize long-term performance and align executive interests with shareholder value creation, a common practice among publicly traded life sciences companies.

Comparison to Industry Standards

• The grant of RSUs with a multi-year vesting schedule is a common compensation practice across the biotechnology sector, comparable to structures seen at companies like Biogen Inc. or Vertex Pharmaceuticals Inc.
• Such grants aim to retain key talent and motivate executives to achieve long-term strategic goals, a standard approach in an industry reliant on sustained innovation and development.

Stakeholder Impact

• Shareholders: Potential minor dilution from future share issuance upon RSU vesting; however, it also signifies management's continued alignment with shareholder interests through equity ownership.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives within the company.

Next Steps

• The newly granted RSUs will vest in four annual installments over four years, with the first installment on January 15, 2027.
• Continued service relationship with the Issuer is required for vesting on each date.

Key Dates

Recommendation

This Form 4 filing reports a routine executive equity grant, which is a standard compensation practice. It does not provide sufficient new information regarding the company's operational performance, financial health, or strategic direction to warrant a change in investment recommendation. Investors should consider this in the broader context of the company's overall financial reports and market position.

Keywords

Scholar Rock Holding Corp, SRRK, Keith Woods, Chief Operating Officer, COO, Restricted Stock Units, RSUs, Insider Transaction, Executive Compensation, Equity Grant, Vesting